Studies

Showing 120 studies.

A5257: Study of Three Compact ARV Regimens for Treatment of Naive HIV-1 Volunteers

DAIDS Number

Research Area

Antiretroviral Strategies

Study Status

Participants Off Study and Primary Analysis Completed

Locality

A5241: Identifying Salvage Regimen w/ & w/o NRTIs Using cPSS and New Agents in the US

DAIDS Number

Research Area

Antiretroviral Strategies

Study Status

Locality

IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Pharmacokinetics, and antiviral activity of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed HIV-Infected Children >2 to <12 years of age and weighing >10 kgs and <50 kgs

Research Area

Study Status

IMPAACT 2035/HVTN 604: Phase I/II Study of the Safety and Immunogenicity of VPM1002 Vaccination and BCG Revaccination against Tuberculosis in South African Pre-Adolescents Living with and without HIV (LEAP)

DAIDS Number

Research Area

Study Status

IMPAACT 2034: Phase I Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis

DAIDS Number

Research Area

Study Status

IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States

DAIDS Number

Research Area

Study Status

IMPAACT 2029: Phase I/II Study of Switching to Fixed Dose Combination Dolutegravir/Rilpivirine among Virologically Suppressed Children and Adolescents Living with HIV

DAIDS Number

Research Area

Study Status

IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV

DAIDS Number

Research Area

Study Status

IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

DAIDS Number

Research Area

Study Status

IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Two to less than 13 Years of Age with and without HIV

DAIDS Number

Research Area

Study Status